Anti CD47 Drugs Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Anti CD47 Drugs Market is segmented By Target Disease Indication (Acute Myeloid Leukemias, Non-Hodgkin Lymphoma, Colorectal Cancers, Diffuse Large Bcell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral Muscositis, Small Cell Lung Cancers), By Type of Molecule (Biologics, Small Molecules), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Anti CD47 Drugs Market Size
Market Size in USD
CAGR42.9%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 42.9% |
| Market Concentration | High |
| Major Players | Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, Forty Seven |
please let us know !
Anti CD47 Drugs Market Analysis
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031. Several major pharmaceutical companies are actively conducting clinical trials for anti-CD47 drugs to treat cancer indicating significant efforts to develop innovative treatment options in oncology.
The anti-CD47 drugs market is expected to witness high growth over the forecast period due to rising cancer incidence globally and increasing R&D investments by companies in developing novel cancer immunotherapies. The market is also driven by the promising clinical trial results of anti-CD47 antibodies that show effectiveness in improving survival rates of cancer patients. If approved, these drugs will have high commercial potential and create new opportunities in the oncology segment.